ReviewFrontiers in neurology2025
Harnessing artificial intelligence for brain disease: advances in diagnosis, drug discovery, and closed-loop therapeutics.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Generative AI in drug repurposing and biomarker discovery: a multimodal approach.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain diseases pose a significant global health challenge due to their complexity and the limitations of traditional medical strategies. Recent advancements in artificial intelligence (AI), especially deep learning models like Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), and Graph Neural Networks (GNNs), offer powerful new tools for analysis. These neural networks are effective at extracting complex patterns from high-dimensional data. By integrating diverse data sources-such as neuroimaging, multi-omics, and clinical information-multimodal AI provides the comprehensive view needed to understand intricate disease mechanisms. This review outlines how these technologies enhance precision drug development and enable closed-loop treatment systems for brain disorders. Key applications include improving diagnostic accuracy, identifying novel biomarkers, accelerating drug discovery through target identification and virtual screening, and predicting patient-specific treatment responses. These AI-driven methods have the potential to shift medicine from a one-size-fits-all model to a personalized approach, with diagnostics and therapies tailored to individual profiles. However, realizing this potential requires addressing significant challenges related to data access, model interpretability, clinical validation, and practical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.